HeartSciences Inc. (HSCS): Nasdaq/NYSE listing notice — HeartSciences receives Nasdaq delisting notice over $1.79M equity vs $2.5M minimum

HeartSciences Inc.

Received Nasdaq deficiency letter on March 19, 2025: stockholders' equity of $1.79M below $2.5M minimum.
Has 45 calendar days, until May 5, 2025, to submit a plan to regain compliance.
If plan accepted, Nasdaq may grant up to 180 days from March 19 to cure; no assurance.
Failure could lead to suspension/delisting, harming liquidity, market price, and financing ability.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

HeartSciences Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

March 19, 2025, HeartSciences Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Stock Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. In its quarterly report for the period ended January 31, 2025, the Company reported stockholders’ equity of $1,786,689, and, as of March 19, 2025, the Company did not meet the alternatives of market value of listed s

View on SEC.gov

Browse all listing & compliance notices →

HeartSciences Inc. filing history →

Source: SEC EDGAR

accession 0001013762-25-001087

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.